The Drug Targeting and Delivery Across Scales Program aims to deliver antibody therapeutics across the blood-brain barrier using adeno-associated virus to target Aβ and Tau pathology. It seeks to develop mRNA therapeutics for various intracellular targets, including Tau. Additionally, the program pioneers the world’s first intravenous targeted non-viral CRISPR therapy by utilising scanning ultrasound for genome editing in the brain. Furthermore, it focuses on delivering novel anti-Tau antibodies, with and without ultrasound, to enhance functional outcomes.

Projects:

– Developing novel vectorized antibodies for enhanced brain delivery

– Developing mRNA therapeutics for the treatment of Alzheimer’s disease and other dementias

– Multivalent brain gene delivery systems using low-CRISPR technology

– Delivering anti-tau antibodies with and without low-intensity ultrasound

– Development of an Integrated CLEIM Imaging Pipeline for MIND-AD CRE Multi-Scale Analysis (MIND-AD CRE Funded; CI Iyer, CI Götz, CI Lazarou, CI Zuryn, AI Padmanabhan)